CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design
暂无分享,去创建一个
K. Blennow | H. Zetterberg | M. Grothe | M. Schöll | Anniina Snellman | T. Karikari | N. Ashton | Juan Lantero-Rodríguez | A. Moscoso | A. Snellman